Who is sponsoring NCT04553627?

NCT04553627 is sponsored by Riverchase Dermatology.

What drugs are being tested in NCT04553627?

Interventions in NCT04553627: ZELTIQ thermoelectric device.

What condition does NCT04553627 study?

NCT04553627 studies Subcutaneous Fat.

Is NCT04553627 still recruiting?

NCT04553627 is currently status unknown. Last updated 19 October 2020.

Last reviewed 2020-10-19 · How we verify

NCT04553627

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Feasibility of Producing the Appearance of a Gluteal Lift Post Cryolipolysis

Status unknown NA Last updated 19 October 2020

What this trial tests

NA trial testing ZELTIQ thermoelectric device in Subcutaneous Fat in 10 participants. Status unknown.

Timeline

15 July 2020

Primary endpoint
30 April 2021

30 May 2021

Quick facts

Lead sponsor	Riverchase Dermatology
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	15 July 2020
Primary completion	30 April 2021
Estimated completion	30 May 2021
Sites	1 location across United States

Drugs / interventions tested

ZELTIQ thermoelectric device

Conditions studied

Subcutaneous Fat — all drugs for Subcutaneous Fat →

Sponsor

Riverchase Dermatology

Who can join

Adults 22 to 50, female only, with Subcutaneous Fat. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety and efficacy of cryolipolysis of the medial infragluteal fold to create the appearance of a gluteal lift.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04553627 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Riverchase Dermatology
Last refreshed: 19 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04553627.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing